Discover and read the best of Twitter Threads about #CARTSM
Most recents (1)
Bispecific antibodies are showing unprecedented single agent activity in relapsed/refractory MM. There are several phase I trials in this setting, let’s see at the data shared at #ASCO22 and #EHA2022 with Teclistamab , Elranatamab and REGN5458 targeting BCMA and…
….Talquetamab targeting GPRC5D. Here is a quick summary of the data #CARTSM #ASCO22_SZU #MedIQ22ASCO Strong work by #mmsm peeps!!
Teclistamab SC showed a response rate of 63%, MRD- 27% at 10-5 via NGS, CRS ~70% (grade 1/2), ICANS 3 % (grade 1/2),median PFS 11.3 months, median DoR 18.4 months, median follow-up 14 months. ascopubs.org/doi/abs/10.120… #CARTSM #ASCO22 #ASCO22_SZU #MedIQ22ASCO #EHA2022
